Go to content
UR Home

The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing CancerIn VitroandIn Vivo

Dreyer, Tobias F. ; Kuhn, Sabine ; Stange, Christoph ; Heithorst, Nadine ; Schilling, Daniela ; Jelsma, Jil ; Sievert, Wolfgang ; Seitz, Stefanie ; Stangl, Stefan ; Hapfelmeier, Alexander ; Noske, Aurelia ; Wege, Anja K. ; Weichert, Wilko ; Ruland, Jürgen ; Schmitt, Manfred ; Dorn, Julia ; Kiechle, Marion ; Reuning, Ute ; Magdolen, Viktor ; Multhoff, Gabriele ; Bronger, Holger


A crucial mode of action of trastuzumab is the labeling of HER2-positive (HER2(+)) tumor cells for the eradication by natural killer (NK) cells, a process called antibody-dependent cellular cytotoxicity (ADCC). However, despite widespread HER2 expression among cancer entities, only a fraction, with robust HER2 overexpression, benefits from trastuzumab therapy. ADCC requires both sufficient ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: datahub@ur.de
0941 943 -5707

Contact persons